Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 71, Issue 1, Pages 85-95Publisher
SPRINGER
DOI: 10.1007/s00262-021-02953-0
Keywords
MIBC; Biomarker; Bladder cancer; Interleukin 6; Interleukin 6 soluble receptor; Urothelial carcinoma
Categories
Funding
- Medical University of Vienna
Ask authors/readers for more resources
The study confirmed that elevated preoperative plasma levels of IL6 and IL6sR are associated with worse oncological disease survival in patients treated with RC for UCB in a large multicenter study. Both biomarkers have the potential to identify patients with adverse pathological features, improve the predictive accuracy of prognostic models, and guide clinical decision making.
Background Preoperative plasma levels of Interleukin 6 (IL6) and its soluble receptor (IL6sR) have previously been associated with oncologic outcomes in urothelial carcinoma of the bladder (UCB); however, external validation in patients treated with radical cystectomy (RC) for UCB is missing. Patients/methods We prospectively collected preoperative plasma from 1,036 consecutive patients at two institutes. These plasma specimens were assessed for levels of IL6 and IL6sR. Logistic and Cox regression analyses were used to assess the correlation of plasma levels with pathologic and survival outcomes. The additional clinical net benefits of preoperative IL6 and IL6sR were evaluated using decision curve analysis (DCA). Results Median IL6 and IL6sR plasma levels were significantly higher in patients with adverse pathologic features. Elevated biomarker levels were independently associated with an increased risk for lymph node metastasis and >= pT3 disease. Both biomarkers were independently associated with recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS). The addition to, respectively, fitted pre- and postoperative prognostic models improved the predictive accuracy for lymph node metastasis, >= pT3 disease, RFS and CSS on DCA. Interpretation We confirmed that elevated preoperative plasma levels of IL6 and IL6sR levels are associated with worse oncological disease survival in patients treated with RC for UCB in a large multicenter study. Both biomarkers hold potential in identifying patients with adverse pathological features that may benefit from intensified/multimodal therapy and warrant inclusion into predictive/prognostic models. They demonstrated the ability to improve the discriminatory power of such models and thus guide clinical decision making.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available